Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 3, 1996, Pages 276-282

  Asthana, Sanjay ^a,b   Greig, Nigel H ^a   Holloway, Harold W ^a   Raffaele, Kathleen C ^a,c   Berardi, Annamaria ^a,d   Schapiro, Mark B ^a   Rapoport, Stanley I ^a   Soncrant, Timothy T ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARECOLINE;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAPHORESIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; FLUSHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARECOLINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MEMORY; MIDDLE AGED; MUSCARINIC AGONISTS; NICOTINIC AGONISTS;

EID: 0029851858     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90054-5     Document Type: Article

References (37)

1. Flicker C, Dean R, Watkins D, Fisher S, Bartus R. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacol Biochem Behav 1983;18:973-81.
2. Helper D, Wenk G, Cribbs B, Olton D, Coyle J. Memory impairments following basal forebrain lesions. Brain Res 1985;346:8-14.
3. Drachman D, Noffsinger D, Sahakian B, Kurdziel S, Fleming P. Aging, memory, and the cholinergic system: a study of dichotic listening. Neurobiol Aging 1980;1:39-43.
4. Drachman DA, Leavitt J, Chicago MA. Human memory and the cholinergic system. Arch Neurol 1974;30: 113-21.
5. Sitaram N, Weingartner H, Gillin J. Human serial learning: enhancement with arecoline and choline and impairment with scopolamine. Science 1978;201: 274-6.
6. Davis K, Mohs R, Tinklenberg J, Pfefferbaum A, Hollister L, Kopell B. Physostigmine: improvement of long-term memory processes in normal humans. Science 1978;201:272-4.
7. Doucette R, Fisman M, Hachinski VC, Mersky H. Cell loss from the nucleus basalis of Meynert in Alzheimer's disease. Can J Neurol Sci 1986;13:435-40.
8. Perry E, Tomlinson B, Blessed G, Bergman K, Gibson P, Perry R. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-9.
9. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.
10. Rinne J, Laakso K, Lonnberg P, Molsa P, Paljarvi L, Rinne J, et al. Brain muscarinic receptors in senile dementia. Brain Res 1985;336:19-25.
11. Mash D, Flynn D, Potter L. Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985;228:1115-7.
12. Caulfield M, Straughan D, Cross A, Crow T, Birdsall N. Cortical muscarinic receptor subtypes and Alzheimer's disease [letter]. Lancet 1982;2:1277.
13. Soncrant TT, Raffaele KC, Asthana S, Berardi A, Morris PP, Haxby JV. Memory improvement without toxicity during chronic low dose intravenous arecoline in Alzheimer's disease. Psychopharmacology (Berl) 1993;112:421-7.
14. Raffaele K, Berardi A, Morris P, Asthana S, Haxby J, Schapiro M, et al. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer Type. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:643-8.
15. Raffaele K, Berardi A, Asthana S, Morris P, Haxby J, Soncrant T. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol Bull 1991;27:315-319.
16. Richards M. Relative potencies of agonists and differential sensitivity to N-ethylmaleimide on muscarinic autoreceptors and postsynaptic receptors in rat hippocampus. J Pharmacol Exp Ther 1990;255:83-9.
17. Herz A, Holzhauser H. Central nicotine-and muscarine-like properties of cholinomimetic drugs with regard to their lipid solubilities. Ann NY Acad Sci 1967;126:21-6.
18. Soncrant T, Holloway H, Greig N, Rapoport S. Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats. Brain Res 1989;487:255-66.
19. Davis R, Charlotte R, Callahan M, Lipinski W, Schwarz R, Dudley D, et al. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. In: Cuello A, editor. Progress in brain research. Amsterdam: Elsevier Science Publishers BV, 1993:439-45.
20. Fisher A, Brandeis R, Karton I, Pittel Z, Dachir S, Sapir M, et al. AF102b: rational treatment strategy for Alzheimer's disease: recent advances. Adv Neurol 1990;51:257-9.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price DL, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
22. Weiner N. Atropine, scopolamine, and related anti-muscarinic drugs. In: Goodman Gilman A, Goodman L, Rall T, Murad F, editors. The pharmacological basis of therapeutics. New York: MacMillan, 1985: 130-44.
23. Shetty H, Daly E, Greig N, Rapoport S, Soncrant T. An automatic reaction control chemical ionization technique in ion trap detector for quantitative plasma profiling of arecoline in treated Alzheimer patients. J Am Soc Mass Spectrom 1991;2:168-73.
24. Testa B, Jenner P. Drug metabolism: chemical and biochemical aspects. New York: Marcel Dekker, 1976:4.
25. Bartus R. Physostigmine and recent memory: effects in young and aged non-human primates. Science 1979;206:1087-9.
26. Bartus RT, Dean RL, Beer B. Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics. Neurobiol Aging 1980;1:145-52.
27. Flood JF, Landry DW, Jarvik ME. Cholinergic receptor interactions and their effects on long-term memory processing. Brain Res 1981;215:177-85.
28. Asthana S, Raffaele K, Greig N, Berardi A, Morris P, Schapiro M, et al. Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease. Psychoneuroendocrinology 1995;20: 623-36.
29. Christie JE, Shering A, Ferguson J, Glen AIM. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981;138:46-50.
30. Tariot P, Cohen R, Welkowitz J, Sunderland T, Newhouse P, Murphy D, et al. Multiple dose areco-line infusions in Alzheimer's disease. Arch Gen Psychiatry 1988;45:901-5.
31. Hollander E, Davidson M, Mohs R, Horvath T, Davis B, Zemishlany Z, et al. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiat 1987;22:1067-8.
32. Wettstein A, Spiegel R. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease and senile dementia of the Alzheimer's disease. Psychopharmacology 1984;84:572-3.
33. Davis K, Hollander E, Davidson M, Davis B, Mohs R, Horvath T. Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 1987;144:468-71.
34. Penn R, Martin E, Wilson R, Fox J, Savoy S. Intraventricular bethanecol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials. Neurology 1988;38:219-22.
35. Bruno G, Mohr E, Gillespie M, Fedio P, Chase T. Muscarinic agonist therapy of Alzheimer's disease-a clinical trial of RS-86. Arch Neurol 1986;43:659-61.
36. Mouradian M, Mohr E, Williams J. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology 1988;38:606-8.
37. Caine E. Cholinomimetic treatment fails to improve memory disorders [letter]. N Engl J Med 1980;303: 585-6.